CEO Stergiou’s Massive RSU Buy Signals Confidence in SELLAS’s Oncology Future
CEO’s 1,065,000‑share RSU purchase signals deep confidence in SELLAS’s oncology pipeline, aligning exec incentives with long‑term value and boosting investor optimism.
- SELLAS LIFE SCIENCES GROUP I
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read